Hodgkin Lymphoma
From the Journals
Study shows childhood IBD increased cancer risk in adulthood
Childhood inflammatory bowel disease was associated with significant increases in the risk of cancer in later life.
News
Representation in cancer clinical trials
ATLANTA—New research suggests some racial/ethnic minority groups are underrepresented in clinical trials for cancer patients in the US. African-...
News
Cancer patients want info about marijuana
A new study suggests cancer patients may be open to using marijuana, but healthcare providers may be falling short in educating patients on...
From the Journals
In Hodgkin lymphoma, HAPLO transplant outcomes match those of conventional transplants
HAPLO transplants may prove a better option than HLA-matched unrelated donor transplants.
News
Report details progress, obstacles in cancer research and care
Deaths from cancer are on the decline in the US, but new cases of cancer are on the rise, according to the 7th annual American Association for...
News
CCSs have higher burden of chronic conditions
Adult survivors of childhood cancer have a greater cumulative burden of chronic health conditions than the general public, according to research...
Feature
Is pain or dependency driving elevated opioid use among long-term cancer survivors?
Rates of opioid prescribing were about 1.2 times higher overall among cancer survivors up to 10 years after diagnosis, compared with matched...
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
News
High healthcare costs follow CCSs into adulthood
New research suggests survivors of childhood cancer can incur high out-of-pocket medical costs into adulthood and may forgo healthcare to lessen...
News
Health Canada approves new use for brentuximab vedotin
Health Canada has issued a non-conditional marketing authorization for brentuximab vedotin (Adcetris). This means the drug is now approved for...
Conference Coverage
Avelumab induces response in Hodgkin lymphoma after failed allo-SCT
LUGANO, SWITZERLAND – The immune checkpoint inhibitor avelumab showed efficacy against classical Hodgkin lymphoma among patients with disease...